Summary of FibroBiologics Special Meeting of Stockholders Company Overview - **Company**: FibroBiologics (NasdaqGM:FBLG) - **Industry**: Biotechnology, specifically focusing on regenerative medicine and fibroblast technology Key Points from the Meeting Corporate Governance - The meeting was presided over by Pete O'Heeron, Founder, Chairman, and CEO, with other board members and executives present [2][17] - A quorum was established with 54,971,343 votes representing approximately 56% of the total votes available [5] Proposals Voted On 1. **Reverse Stock Split**: Proposal to amend the certificate of incorporation for a reverse stock split at a ratio between 1-for-5 and 1-for-30, approved [9][15] 2. **Issuance of Shares**: Multiple proposals to approve the issuance of shares upon the exercise of outstanding common warrants, all approved: - Up to 12,110,203 shares from a securities purchase agreement dated November 18, 2025 [10][15] - Up to 4,477,614 shares from agreements dated November 24, 2025, and 313,433 shares from an engagement letter dated November 10, 2025 [11][15] - Up to 5,227,275 shares from agreements dated December 14, 2025, and 365,909 shares from an engagement letter [12][15] 3. **Adjournment of Meeting**: Approved to solicit additional votes if necessary [13][15] Corporate Update Highlights - **Mission**: To harness the immune modulation and regenerative potential of fibroblasts to treat and cure chronic diseases [18] - **Clinical Trials**: - Currently conducting a Phase 1/2 clinical trial for diabetic foot ulcers [19] - IND submitted for psoriasis at the end of December 2025, with plans for IND-ready assets for multiple sclerosis and degenerative disc disease [19] - **Financial Position**: Clean balance sheet with $4.9 million in cash as of September 30, 2025, and over 270 issued and pending patents [19][20] Technology and Innovation - **Fibroblast Technology**: - Fibroblasts are positioned as a promising alternative to stem cells for regenerative medicine due to their regenerative and immune-modulating properties [21][22] - Fibroblasts are abundant, well-characterized, and offer advantages in non-invasive sourcing, immune modulation, and cost-effectiveness [22][23] - **Pipeline**: Focus on diabetic foot ulcers, multiple sclerosis, degenerative disc disease, and psoriasis, with potential applications in longevity and cancer treatment [30][31][32] Market Opportunity - **Diabetic Foot Ulcers**: Approximately 33 million diabetes patients develop diabetic foot ulcers, representing a significant commercial opportunity [24] - **Multiple Sclerosis**: Affects 2.9 million globally, with a focus on addressing root causes rather than just symptom management [27] - **Psoriasis**: Affects 123 million worldwide, with current treatments being inadequate; fibroblast modulation offers a new approach [30] Future Outlook - The company aims to become a leader in regenerative medicine, focusing on impactful innovations rather than size [19] - Plans to advance clinical trials and potentially bring products to market rapidly, contingent on FDA approvals and trial results [36] Additional Insights - The meeting emphasized the importance of innovation, teamwork, and a commitment to curing chronic diseases rather than merely managing symptoms [19][20] - The leadership team has over 60 years of combined experience in medical innovation and capital markets, providing strategic guidance for the company's direction [20] This summary encapsulates the key discussions and proposals from the FibroBiologics special meeting, highlighting the company's strategic focus on fibroblast technology and its potential to transform the treatment of chronic diseases.